Distribution of MED12 mutations in fibroadenomas and phyllodes tumors of the breast—implications for tumor biology and pathological diagnosis
- 30 April 2015
- journal article
- research article
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 54 (7) , 444-452
Abstract
Somatic mutations in exon 2 of MED12 have been described in benign and malignant smooth muscle cell tumors suggesting a functional role in these neoplasms. Recently fibroadenomas of the breast were also reported to harbor MED12 mutations. Hence, we explored MED12 mutations in fibroepithelial tumors of the breast, histological subtypes of fibroadenomas and phyllodes tumors, to validate and extend previous efforts. Using conventional Sanger sequencing, we profiled 39 cases of fibroepithelial breast tumors comprising classic histological subtypes of fibroadenomas as well as benign and malignant phyllodes tumors for mutations in exon 2 of MED12. MED12 mutations were detected in 60% of all tumor samples with the majority being missense mutations affecting codon 44. Additionally, we report novel in‐frame deletions that have not been described previously. Sixty‐two percent of the fibroadenomas harbored mutated MED12 with intracanalicular fibroadenomas being the most frequently mutated histological subtype (82%). Of note, 8/11 of benign phyllodes tumors had MED12 mutations while only 1/5 of malignant phyllodes tumors showed mutations in exon 2 of MED12. In conclusion, we confirm the frequent occurrence of MED12 mutations in fibroadenomas, provide evidence that most intracanalicular fibroadenomas closely resembling benign phyllodes as well as benign phyllodes tumors harbor MED12 mutations, and conclude that MED12 mutations in malignant phyllodes tumors appear to be relatively rare.Keywords
Funding Information
- German Cancer Consortium (DKTK)
This publication has 34 references indexed in Scilit:
- Myoepithelial and epithelial–myoepithelial, mesenchymal and fibroepithelial breast lesions: updates from the WHO Classification of Tumours of the Breast 2012Journal of Clinical Pathology, 2013
- MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor SignalingCell, 2012
- Prevalence of MED12 mutations in uterine and extrauterine smooth muscle tumoursHistopathology, 2012
- Whole Exome Sequencing in a Random Sample of North American Women with Leiomyomas Identifies MED12 Mutations in Majority of Uterine LeiomyomasPLOS ONE, 2012
- PIK3CA Hotspot Mutation Scanning by a Novel and Highly Sensitive High-Resolution Small Amplicon Melting Analysis MethodThe Journal of Molecular Diagnostics, 2010
- The human Mediator complex: a versatile, genome-wide regulator of transcriptionTrends in Biochemical Sciences, 2010
- A comprehensive genetic profile of phyllodes tumours of the breast detects important mutations, intra‐tumoral genetic heterogeneity and new genetic changes on recurrenceThe Journal of Pathology, 2008
- Histological features useful in the distinction of phyllodes tumour and fibroadenoma on needle core biopsy of the breastHistopathology, 2007
- Mediator Modulates Gli3-Dependent Sonic Hedgehog SignalingMolecular and Cellular Biology, 2006
- Long-Term Risk of Breast Cancer in Women with FibroadenomaNew England Journal of Medicine, 1994